Bayer (ETR:BAYN) and Versant Ventures said today that the 2 groups closed a $225 million Series A financing round to launch BlueRock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies. The funds are estimated to support the company for 4 years as it advances cell therapy clinical programs for cardiovascular and degenerative diseases. “Accessing […]
Versant Ventures and James Mazzo agreed that Mazzo will "suspend any activities" at the venture capital shop following his indictment last month on insider trading charges.
September 24, 2014 by Brad Perriello
California-based Ceterix Orthopaedics plans to boost its marketing efforts with the help of $18 million in new financing.
The company hopes to widen the reach of its surgical tools, which help physicians place stitches in hard-to-reach places while protecting other tissue. Ceterix’s technology is currently in use by more than 100 physicians in the U.S., according to a company statement.
Sequent Medical said it raised a Series D round worth $20 million from its slate of previous investors, led again by Delphi Ventures.
Domain Associates, US Venture Partners and Versant Ventures also participated, Sequent said.
Medical device investment group Versant Ventures is looking to raise a new $250 million fund, the group’s 5th fund so far.
The funding round should be a short one, although the 1st sale has yet to occur, according to regulatory filings. The group is offering pooled investment fund interests.
James Mazzo has put 35 years into the optics and ophthalmology business, so it was no surprise that he got involved with AcuFocus and its device for treating presbyopia. Mazzo, who stepped down from leading Abbott Medical Optics earlier this year, added another title to his resume that’s more of a departure: He’s the 1st "operating partner" at Versant Ventures.